Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Device Approval”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,657 records · Page 92Linked to original sources

FDA: friend or foe?

Delays in FDA product approvals have weakened the US medical device market. Reduced investment returns and the erosion of industry's confidence in FDA procedures have slowed the introduction of new products and threatened the market's potential for growth. This article examines the background to those issues and describes FDA's attempts to overcome its procedural shortcomings.

Drug Approval↗

Financial disclosure by clinical investigators--FDA. Final rule.

The food and Drug Administration (FDA) is issuing regulations requiring the sponsor of any drug, including a biological product, or device marketing application (applicant), to submit certain information concerning the compensation to, and financial interests of any clinical investigator conducting certain clinical studies. This requirement will apply to any covered clinical study of a drug or device submitted in a marketing application that the applicant or FDA relies on to establish that the product is effective, including studies that show equivalence to an effective product, or that make a significant contribution to the demonstration of safety. This final rule requires applicants to certify to the absence of certain financial interests of clinical investigators and/or disclose those financial interests, as required, when covered clinical studies are submitted to FDA in support of product marketing. This regulation is intended to ensure that financial interests and arrangements of clinical investigators that could affect reliability of data submitted to FDA in support of product marketing are identified and disclosed by the sponsor of any drug, biological product, or device marketing application. If the applicant does not include certification or disclosure, or both, if required, or does not certify that it was not possible to obtain the information, the agency may refuse to file the application. FDA intends to propose to extend these requirements to submissions for marketing approval related to human foods, animal foods, and animal drugs in a subsequent issue of the Federal Register.

Conflict of Interest↗

Computerized scanning devices for Pap smear screening: current status and critical review.

Automation of the Pap smear has taken almost half of a century. Two systems have recently received FDA approval for routine use as quality control (rescreening) devices. Technical triumphs are overshadowed by current conflicts among cytopathology professionals, clinicians, patients, and device manufacturers. The historic perspective of this potentially volatile situation provides the backdrop for possible solutions based on the scientific validity of this evolving technology.

Diagnosis, Computer-Assisted↗

International recommendations and guidelines for the safe use of diagnostic ultrasound in medicine.

Modern sophisticated ultrasonographic equipment is capable of delivering substantial levels of acoustic energy into the body when used at maximum outputs. The risk of producing bioeffects has been studied by international expert groups during symposia supported by the World Federation for Ultrasound in Medicine and Biology (WFUMB). These have resulted in the publication of internationally accepted conclusions and recommendations. National ultrasound safety committees have published guidelines as well. These recommendations and safety guidelines offer valuable information to help users apply diagnostic ultrasound in a safe and effective manner. Acoustic output from ultrasound medical devices is directly regulated only in the USA and this is done by the Food and Drug Administration (FDA). However, there is also a modern trend towards self-regulation which has implications for the worldwide use of diagnostic ultrasound. It has resulted in a move away from the relatively simple scheme of FDA-enforced, application-specific limits on acoustic output to a scheme whereby risk of adverse effects of ultrasound exposure is assessed from information provided by the equipment in the form of a real-time display of safety indices. Under this option, the FDA allows a relaxation of some intensity limits, specifically approving the use of medical ultrasound devices that can expose the fetus or embryo to nearly eight times the intensity that was previously allowed. The shift of responsibility for risk assessment from a regulatory authority to the user creates an urgent need for awareness of risk and the development of knowledgeable and responsible attitudes to safety issues. To encourage this approach, it is incumbent on authorities, ultrasound societies and expert groups to provide relevant information on biological effects that might result from ultrasonographic procedures. It is obvious from the continued stream of enquiries received by ultrasound societies that effective dissemination of such knowledge requires sustained strenuous effort on the part of ultrasound safety committees. There is a strong need for continuing education to ensure that appropriate risk/benefit assessments are made by users based on an appropriate knowledge of the probability of biological effects occurring with each type of ultrasound procedure. The primary purpose of this paper is to draw attention to current safety guidelines and show the similarities and areas of general agreement with those issued by the parent ultrasound organisation, the WFUMB. It is equally important to identify gaps in our knowledge, where applicable.

Female↗

Drug approval highlights for 2003.

In the past 12 months, the FDA has approved important new pharmaceutical drugs and devices of particular interest to primary health care providers. The drugs include: Oxytrol (for urinary incontinence), Valtrex (for reducing the risk of heterosexual transmission of genital herpes), Femring (for vaginal delivery of hormone therapy), Uroxatral (for benign prostatic hypertrophy), Levitra (for erectile dysfunction), Flumist (for preventing influenza), Xolair (for asthma), Raptiva (for psoriasis), Cubicin (for skin infections), Crestor (for hypercholesterolemia), and Coreg (for severe heart failure).

Acyclovir↗

New devices enhance hospital results of coronary angioplasty.

After rigorous screening by means of registries and controlled trials, various atherectomy devices, excimer laser catheters, and endoluminal stents were approved for general clinical use. Few data are available describing their safety and effectiveness after approval. This analysis was undertaken to assess the impact on patient outcomes of the unrestricted clinical application of new transcatheter devices for coronary angioplasty. Thirty-six cardiologists performed 3,113 transcatheter procedures during 1995. Each chose the transcatheter modality best suited to the clinical and angiographic features of the patient. Baseline clinical and angiographic data and initial outcome were recorded by cardiac catheterization laboratory personnel. In-hospital events were obtained by independent chart review. Balloon angioplasty alone was employed in 1,089 (35.0%) patients. A stent was deployed after balloon angioplasty in 1,029 (33.1%) patients. An atherectomy or laser device was used without stent support in 631 (20.3%) patients, and stent support was added in an additional 364 (11.7%) patients. In all three new device categories the angiographic success (final luminal narrowing <50%) rate was better than in balloon angioplasty for type-C lesions and for chronic occlusions. The frequency of adverse events in the aggregate was not increased with device use, but the frequency of coronary artery bypass surgery was reduced with stent use. The frequency of non-Q-wave myocardial infarction was greater with devices than with balloon angioplasty alone. After adjustment for the differences in baseline clinical and angiographic variables by means of multivariate analysis, each of the three new device categories was independently associated with an increased chance of angiographic and procedural success compared to balloon angioplasty. The availability of new transcatheter devices for clinical practice enhances patient outcomes during hospitalization for the procedure.

Aged↗

[A set of devices for monitoring radon and thoron in various media].

A new class of devices has been designed for rapid and integral measurements of environmental radon and thoron at the levels much lower than the approved normal ones. The operation principle of the devices' transducers is based on deposition of ionized decay byproducts of radon and thoron onto the surface of a semiconductor detector in the measuring chamber, followed by recording of their alpha-radiation. The devised radiometers have some advantages, namely: a high sensitivity (10 Bk/m3), simultaneously record the air levels of radon and thoron in the spectrometric operation of measurements, require no changeable aerosol filters and potent air blowers. The available serial foreign analogues of radiometers have worse parameters and functional capacities than the designed PPA-01M- and PPA-03 type ones.

Air↗

Medical devices; 30-day notices and 135-day PMA supplement review--FDA. Direct final rule; withdrawal.

The Food and Drug Administration (FDA) published, in the Federal Register of April 27, 1998 (63 FR 20530), a direct final rule to implement the amendments to the premarket approval provisions of the Federal Food, Drug, and Cosmetic Act, as amended by the Food and Drug Administration Modernization Act of 1997 (FDAMA). The comment period closed on July 13, 1998. FDA is withdrawing the direct final rule because the agency received significant adverse comment.

Device Approval↗

The Food and Drug Administration and atrial defibrillation devices.

CONTEXT: Atrial fibrillation is a common arrhythmia. It leads to significant morbidity and mortality, primarily from the increased incidence of stroke. The implantable atrial defibrillator, a new therapeutic option for the management of atrial fibrillation, is currently undergoing Food and Drug Administration (FDA) scrutiny for approval to market in the United States. DATA SOURCES: A review of the basic epidemiology of atrial fibrillation, as well as the current status of accepted treatment options in light of the development of the implantable atrial defibrillator, was conducted. A literature search using the terms atrial fibrillation, implantable defibrillator, Food and Drug Administration, medical devices, and medical device regulatory law was conducted using the MEDLINE and Current Contents databases. RESULTS: Currently, there is no consensus on the optimal treatment of atrial fibrillation. Despite the lack of definitive studies showing overall benefit associated with maintaining sinus rhythm in patients in atrial fibrillation, the implantable atrial defibrillator may soon reach the general market. We examine the FDA process for the evaluation of this new medical device and discuss implications for the patient, physician, industry, and health insurers. CONCLUSIONS: Current FDA approval processes for new devices are a compromise between (a) the needs for expediency and encouraging innovation by the medical device industry and (b) the need to ensure that new devices will contribute to improved patient outcomes. We suggest alternative FDA-approval processes that address these issues.

Atrial Fibrillation↗

In-vivo experience with the Triflo trileaflet mechanical heart valve.

BACKGROUND AND AIM OF THE STUDY: The in-vivo performance of the Triflo trileaflet mechanical valve was evaluated in an ovine model. The aim of long-term follow up was to gather site-specific performance data demonstrating device safety, as required for regulatory approval of this new valve design, prior to its use in clinical trials. METHODS: The Triflo trileaflet valve was implanted in 26 sheep using 29-mm mitral (n=8; animal body weight 63.3 +/- 10.3 kg, age 112.0 +/- 30.7 weeks) or 21-mm aortic mechanical valves (n=19; body weight 73.0 +/- 4.36 kg, age 112.6 +/- 23.6 weeks) using standard techniques. Animals were allocated to 150- or 365-day survival cohorts. The 150-day cohort was further subdivided into mitral valve (n=6) and aortic valve (n=11) implants. The 365-day cohort was organized into aortic (n=7) and mitral (n=2) implants. Angiography, echocardiography, and pathology were performed to assess valve performance. RESULTS: Angiographically monitored pressure measurements for the trileaflet mitral valve at 150 and 365 days were within established ranges in terms of mean aortic pressure, systolic and diastolic aortic pressure, and left ventricular end-diastolic pressure. In animals receiving a mitral valve the transvalvular gradient was 3.5 +/- 0.71 mmHg at 365 days, and 0.2 +/- 0.4 mmHg at 150 days. The Triflo mitral valve had only mild (physiologic) regurgitation. Cardiac output was within normal limits in animals receiving the Triflo valve in the aortic position. Laboratory values reflected no ongoing infection or destruction of blood cells as a result of device implantation. No significant abnormality was noted at necropsy in any animal, except for evidence of thromboembolic events in the kidneys (4-20%). Pathological evaluation was reflected by mild to moderate fibrous tissue formation at the inflow orifice (n=15), and minimal growth was observed in the outflow tract of one valve. This was consistent with that seen in sheep implanted with a standard St. Jude Medical bileaflet valve. CONCLUSION: The study results showed the Triflo valve to perform to safety levels comparable with those of the standard St. Jude Medical bileaflet design, when implanted in the aortic and mitral positions. Additional analysis of historic control data suggested that the trileaflet valve design may offer a reduction in outflow tract obstruction by allowing for a greater effective orifice area index when compared to an equal-sized-orifice bileaflet valve. Notably, the Triflo valve was associated with a statistically significant reduction in myocardial hypertrophy, further reducing the potential for patient-prosthesis mismatch. Overall, the Triflo valve appeared to more closely emulate the hemodynamic properties of the native tissue valve than the traditional bileaflet design. Hence, the trileaflet design may offer the function of a tissue valve while retaining the durability of the mechanical valve.

Animals↗

Favorable early results of gastric banding for morbid obesity: the American experience.

BACKGROUND: In 2001 a new device for surgical weight loss was approved by the Food and Drug Administration (Lap-Band, Inamed Health). We describe initial results of laparoscopic gastric banding for morbid obesity in two American academic centers. METHODS: Prospective data was collected on consecutive morbidly obese patients undergoing laparoscopic adjustable gastric banding, and evaluated retrospectively. RESULTS: Four hundred forty-five consecutive patients underwent Lap-Band from May 2001 through December 2002. The 103 men and 341 women had an average age of 42.1 years (range 17-72 years) and an average body mass index (BMI) of 49.6 kg/m2 (range 35.2-92.2 kg/m2). One operation required conversion to laparotomy due to bleeding; the rest were completed laparoscopically. Mean length of stay was 1.1 days (range 1-10 days). There was one death. Additional complications included band slippage in 14 patients (3.1%), gastric obstruction without slip in 12 (2.7%), port migration in 2 (0.4%), tubing disconnections in 3 (0.7%), and port infection in 5 (1.1%). Two bands (0.4%) were removed due to intraabdominal abscess 2 months after placement. There was one band erosion (0.2%) and no clinically significant esophageal dilation. Ninety-nine patients have 1-year follow-up and have lost an average of 44.3% excess body weight. CONCLUSION: Laparoscopic gastric banding has much to offer the morbidly obese. We present data showing weight loss rivaling gastric bypass and acceptably low complications. These results parallel success with this device outside America.

Adolescent↗

New method for treatment of high hepaticocholedoch strictures (experimental research).

The purpose of the investigation was to achieve hepaticocholedoch recovery with preserved sphincter apparatus. The experiments were carried out on 25 mongrel dogs of both sexes with body weight 12-25 kg. The animals were divided into 3 groups. The hepatocholedoch strictures were induced in the animals of group I (n=10) and II (n=10). On the 4th day following modeling the animals of group II were subjected to relaparatomy, stricture removal and hepatocholedoch distraction by means of distraction device developed by prof. Kakabadze (patent request submitted for approval). On the 18th day after the surgical procedure the animals have undergone the surgery, the distraction device was removed and the anatomical integrity of biliary tract was restored by bilio-biliary anastomosis. Performed investigations have shown that all of the animals of group I have died on the several time points after the surgery. The cause of death was cholestasis. As to animals of group II, 2 dogs have died on 24 and 35 days after the surgery because of technical shortages of the bilio-biliary anastomosis. The rest 8 experimental animals undergo surgery and postoperative period normally and they were under observation in vivarium standard conditions correspondingly. The i.v. cholangiography, performed in survived animals during postoperative period, showed compete contrast liquid flow into the duodenum. The histological test performed during distraction showed mucosal layer sclerosis. Distraction and afford made evident influence on the muscular fibers through the duct axis. Their elongation and attenuation was mentioned after 3 days from distraction. The fibroblasts local accumulation was seen. The hepaticocholedoch mucosal complete recovery was seen after apparatus was taken out and the bilio-biliary anastomosis was done. Thus, new method of hepaticocholedoch strictures surgical correction elaborated by us allows us to restore anatomical integrity of biliary tract with preserved Oddi sphincter.

Animals↗

Integrated data acquisition system for medical device testing and physiology research in compliance with good laboratory practices.

In seeking approval from the US Food and Drug Administration (FDA) for clinical trial evaluation of an experimental medical device, a sponsor is required to submit experimental findings and support documentation to demonstrate device safety and efficacy that are in compliance with Good Laboratory Practices (GLP). The objective of this project was to develop an integrated data acquisition (DAQ) system and documentation strategy for monitoring and recording physiological data when testing medical devices in accordance with GLP guidelines mandated by the FDA. Data aquisition systems were developed as stand-alone instrumentation racks containing transducer amplifiers and signal processors, analog-to-digital converters for data storage, visual display and graphical user-interfaces, power conditioners, and test measurement devices. Engineering standard operating procedures (SOP) were developed to provide a written step-by-step process for calibrating, validating, and certifying each individual instrumentation unit and the integrated DAQ system. Engineering staff received GLP and SOP training and then completed the calibration, validation, and certification process for the individual instrumentation components and integrated DAQ system. Eight integrated DAQ systems have been successfully developed that were inspected by regulatory affairs consultants and determined to meet GLP guidelines. Two of these DAQ systems were used to support 40 of the pre-clinical animal studies evaluating the AbiCor artificial heart (ABIOMED, Danvers, MA). Based in part on these pre-clinical animal data, the AbioCor clinical trials began in July 2001. The process of developing integrated DAQ systems, SOP, and the validation and certification methods used to ensure GLP compliance are presented in this article.

Equipment and Supplies↗

Partially implantable piezoelectric middle ear hearing device. Long-term results.

In accordance with the 1992-1993 Japanese government approval of production and implementation in the health insurance system of the partially implantable piezoelectric middle ear device (P-MEI), we are conducting follow-up studies on the implanted patients. This article reports the results of the 16 cases, which are regarded as successful implantations because these patients are using the device every day as long as they are awake. A successful case is presented to illustrate the efficacy of the device.

Adult↗

Foot spas as a cause of burns.

Within 2 weeks the authors saw two patients with deep burns of their feet caused by foot spas. Both devices had been used according to the manufacturers' instructions and had been approved by The Danish Electric Material Control. Examination however showed that the bottom plate of these devices reached unacceptably high temperatures that far exceeded the stipulation for approval. As a consequence of this report, the rules for approval of foot spas in Denmark have been changed, as well as a warning to persons at risk that should be included in the directions for use in the future.

Adult↗

Left ventricular assist devices as destination therapy.

Although an estimated 16,500 Americans annually could benefit from a heart transplant, in 1999 only 2184 heart transplants were performed in the United States. These statistics emphasize the severity of the shortage of available hearts for transplantation. Circulatory support provided by an implantable Left Ventricular Assist Device (LVAD) that meets Food and Drug Administration approval as destination therapy is a promising alternative that impacts patient survival. As medical technology creates smaller implantable battery-powered circulatory assist devices that allow patients to safely live independently in the community, nursing's role must change in response. Long-term LVAD patients require strategic, anticipatory planning for extended care and emergency preparedness for mechanical support. Therefore, practitioners must familiarize themselves with these devices as they care for larger numbers of patients with implanted LVADs who require assessment and treatment of noncardiac problems during their lengthened lifespan.

Heart-Assist Devices↗

Pedicle screw fixation in spinal disorders: a European view.

Continuing controversy over the use of pedicular fixation in the United States is promoted by the lack of governmental approval for the marketing of these devices due to safety and efficacy concerns. These implants have meanwhile become an invaluable part of spinal instrumentation in Europe. With regard to the North American view, there is a lack of comprehensive reviews that consider the historical evolution of pedicle screw systems, the rationales for their application, and the clinical outcome from a European perspective. This literature review suggests that pedicular fixation is a relatively safe procedure and is not associated with a significantly higher complication risk than non-pedicular instrumentation. Pedicle screw fixation provides short, rigid segmental stabilization that allows preservation of motion segments and stabilization of the spine in the absence of intact posterior elements, which is not possible with non-pedicular instrumentation. Fusion rates and clinical outcome in the treatment of thoracolumbar fractures appear to be superior to that achieved using other forms of treatment. For the correction of spinal deformity (i.e., scoliosis, kyphosis, spondylolisthesis, tumor), pedicular fixation provides the theoretical benefit of rigid segmental fixation and of facilitated deformity correction by a posterior approach, but the clinical relevance so far remains unknown. In low-back pain disorders, a literature analysis of 5,600 cases of lumbar fusion with different techniques reveals a trend that pedicle screw fixation enhances the fusion rate but not clinical outcome. The most striking finding in the literature is the large range in the radiological and clinical results. For every single fusion technique poor and excellent results have been described. This review argues that European spine surgeons should begin to back up the evident benefits of pedicle screw systems for specific spinal disorders by controlled prospective clinical trials. This may prevent forthcoming medical licensing authorities from restricting the use of pedicle screw devices and dictating the practice of spinal surgery in Europe in the near future.

Bone Screws↗

The Calgary protocol for bracing of pectus carinatum: a preliminary report.

BACKGROUND: The optimal treatment of pectus carinatum (PC) deformities is unclear. We propose a nonoperative approach using a lightweight, patient-controlled dynamic chest-bracing device. MATERIAL AND METHODS: With ethical approval, 24 patients with PC were treated at the Alberta Children's Hospital between January 1998 and April 2005. There were 6 (25%) females and 18 (75%) males, with a mean age of 12.9 years at the onset of treatment. Treatment involved fitting of a lightweight, patient-controlled chest brace, worn for 23 hours per day (correction phase [CP]) until the convex deformity was corrected. Following correction of the deformity, bracing was reduced to 8 hours per day (maintenance phase) until axial skeletal maturation ceased. Monitoring was done by measurement of the external pectus carinatum protrusion as well as subjective patient and surgeon appraisal of appearance and exercise tolerance. RESULTS: Nineteen (79.2%) patients have completed initial treatment (mean CP time, 4.3 +/- 2.1 months). There were 3 patients (12.5%) who were noncompliant, and 2 (8.3%) are still in the initial CP phase of therapy. Fourteen (58.3%) patients are presently in maintenance phase, nocturnally braced, and 2 (8.3%) have completed therapy. In patients completing initial treatment, the protrusion pectus carinatum protrusion (pre 22 +/- 6 vs post 6.0 +/- 6.2) and subjective appearance (change + 1.8+/-0.4) showed a significant improvement (P < .001 for both) with no change in exercise tolerance. CONCLUSION: Compressive bracing results in a significant subjective and objective improvement in PC appearance in skeletally immature patients. However, patient compliance and diligent follow up appear to be paramount for the success of this method of treatment. Further studies are required to show the durability of this method of treatment.

Adolescent↗